---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-035737"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-09-11T23:59:59+00:00"
generated_at: "2026-05-31T05:26:44.961068+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+

## Summary
- Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.
- FDA Pre-IND meeting gave positive feedback; waived animal toxicology/PK studies for Bria-PROS+ prostate cancer trial.
- No drug-related discontinuations reported in the Phase 2 study; ongoing Phase 3 pivotal study NCT06072612.
- Poster presentation at SITC 2024 (Nov 8, Houston) on novel targeted immunotherapy candidates.

## SEC filing metadata
- accession: 0001493152-24-035737
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/0001493152-24-035737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-035737
- JSON: https://secwatch.observer/filing/0001493152-24-035737.json
- Plain text: https://secwatch.observer/filing/0001493152-24-035737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.